Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
21.08
+0.14 (0.67%)
At close: May 14, 2025, 4:00 PM
21.09
+0.01 (0.05%)
After-hours: May 14, 2025, 6:34 PM EDT
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 13 professional analysts, the 12-month price target for Travere Therapeutics stock ranges from a low of $20 to a high of $47. The average analyst price target of $33.31 forecasts a 58.02% increase in the stock price over the next year.
Price Target: $33.31 (+58.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 6 | 6 | 8 | 8 | 7 | 7 |
| Hold | 3 | 2 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 13 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +42.31% | May 2, 2025 |
| Stifel | Stifel | Hold Maintains $22 → $23 | Hold | Maintains | $22 → $23 | +9.11% | May 2, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 23, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +122.96% | Apr 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $45 → $47 | Strong Buy | Maintains | $45 → $47 | +122.96% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
392.45M
from 233.18M
Increased by 68.31%
Revenue Next Year
610.85M
from 392.45M
Increased by 55.65%
EPS This Year
-1.47
from -4.08
EPS Next Year
1.01
from -1.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 461.9M | 840.2M | 849.4M | ||
| Avg | 392.5M | 610.9M | 712.8M | ||
| Low | 324.5M | 433.7M | 575.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.1% | 114.1% | 39.1% | ||
| Avg | 68.3% | 55.7% | 16.7% | ||
| Low | 39.2% | 10.5% | -5.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | 3.47 | 3.39 | ||
| Avg | -1.47 | 1.01 | 1.74 | ||
| Low | -2.39 | -0.96 | 0.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 236.6% | ||
| Avg | - | - | 72.6% | ||
| Low | - | - | -68.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.